FibroGen Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
0.31
0
(-0.84%)
Volume:
1,147,954
52 week range:
0.18 - 1.53
Market Cap:
30.859M
Company Description:
FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is in Phase III.